1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Stearoyl-CoA Desaturase (SCD)

Stearoyl-CoA Desaturase (SCD)

Stearoyl-CoA desaturase (SCD) is a key regulator of membrane fluidity, turns over rapidly, and represents a model for selective degradation of short-lived proteins of the endoplasmic reticulum (ER). SCD is a rate-limiting lipogenic enzyme that plays an integral role in catalyzing the synthesis of monounsaturated fatty acids, chiefly oleate and palmitoleate. Both contribute a major part of the biological membrane. Numerous SCD isoforms exist in mouse and humans, i.e., SCD-1 to SCD-4 and SCD-1 and SCD-5, respectively.

Overexpression of SCD is evident and implicated in metabolic diseases such as diabetes and non-alcoholic fatty liver disease. SCD also stimulates canonical Wnt pathway and YAP activation in support of stemness and tumorigenesis. SCD facilitates metabolic reprogramming in cancer which is mediated, at least in part, by regulation of AKT, AMPK, and NF-kB via MUFAs. From the biological viewpoint, hyperexpression of SCD1 causes many metabolic disorders including obesity, insulin resistance, hypertension, and hypertriglyceridemia, etc. SCD1 is a pharmacological target in the treatment of obesity, diabetes and other metabolic diseases.

Stearoyl-CoA Desaturase (SCD) Related Products (17):

Cat. No. Product Name Effect Purity
  • HY-50709
    A939572
    Inhibitor 99.98%
    A939572 is a potent, and orally bioavailable stearoyl-CoA desaturase1 (SCD1) inhibitor with IC50 values of <4 nM and 37 nM for mSCD1 and hSCD1, respectively.
  • HY-15823
    CAY10566
    Inhibitor 99.73%
    CAY10566 is a potent, orally bioavailable and selective stearoyl-CoA desaturase1 (SCD1) inhibitor with IC50s of 4.5 and 26 nM in mouse and human enzymatic assays, respectively. CAY10566 also shows excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells (IC50=7.9 nM or 6.8 nM).
  • HY-13070
    MK-8245
    Inhibitor 98.99%
    MK-8245 is a potent, liver-targeted stearoyl-CoA desaturase (SCD) inhibitor, with IC50s of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with antidiabetic and antidyslipidemic efficacy.
  • HY-15700
    PluriSIn 1
    Inhibitor 99.64%
    PluriSIn 1 (NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD), and is a pluripotent cell-specific inhibitor.
  • HY-15822
    MF-438
    Inhibitor 99.92%
    MF-438 is a potent and orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor with an IC50 of 2.3 nM for rSCD1.
  • HY-150125
    SCD1-IN-1
    Inhibitor
    SCD1-IN-1 is a SCD1 inhibitor (IC50: 5.8 nM). SCD1-IN-1 can be used in the research of dermatologic condition.
  • HY-113638
    CVT-11127
    Inhibitor
    CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer.
  • HY-19762
    GSK1940029
    Inhibitor 99.65%
    GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD) inhibitor extracted from patent WO/2009060053 A1, compound example 16.
  • HY-11034
    CVT-12012
    Inhibitor 99.16%
    CVT-12012 is a potent and orally bioavailable stearoyl-coA desaturase (SCD) inhibitor, with IC50s of 38 nM, 6.1 nM for rat microsomal and human HEPG2, respectively.
  • HY-112812
    SCD1 inhibitor-1
    Inhibitor 99.45%
    SCD1 inhibitor-1 is a potent and liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitor.
  • HY-N6807
    Elemicin
    Inhibitor 98.39%
    Elemicin is a alkenylbenzene widely distributed in many herbs and spices. Elemicin inhibits Stearoyl-CoA Desaturase 1 (SCD1) by metabolic activation. Elemicin is one of the main components in aromatic food and has antimicrobial, antioxidant, and antiviral activities. Elemicin possesses genotoxicity and carcinogenicity.
  • HY-141525
    SCD1 inhibitor-4
    Inhibitor 98.60%
    SCD1 inhibitor-4 is a potent, orally active stearoylCoA desaturase-1 (SCD1) inhibitor. SCD1 inhibitor-4 can be used for the research of diabetes.
  • HY-100249
    XEN723
    Inhibitor 99.60%
    XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase (SCD1) with IC50s of 45 and 524 nM in mouse and HepG2 cell, respectively.
  • HY-13077
    MK-8245 Trifluoroacetate
    Inhibitor 98.09%
    MK-8245 trifluoroacetate is a liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with anti-diabetic and anti-dyslipidemic efficacy.
  • HY-102045
    T-3764518
    Inhibitor 99.90%
    T-3764518 is a novel and potent stearoyl coenzyme A desaturase (SCD) inhibitor with an IC50 of 4.7 nM.
  • HY-124751
    YTX-465
    Inhibitor 99.87%
    YTX-465 is a stearoyl-CoA desaturase (Ole1/SCD) inhibitor. YTX-465 inhibits Ole1 and SCD1 with IC50s of 0.039 μM and 30.4 μM, respectively. YTX-465 can be used in the research of Parkinson’s disease and other synucleinopathies.
  • HY-127143
    Sterculic acid
    Inhibitor ≥99.0%
    Sterculic acid is a stearoyl-CoA desaturase-1 (SCD1) inhibitor. Sterculic acid specifically inhibits the delta-9 desaturase (Δ9D) activity with an IC50 value of 0.9 μM.
  • HY-139077
    SCD1 inhibitor-3
    Inhibitor
    SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer.